Top Ten Pharmaceutical Events In 2007
This article was originally published in PharmAsia News
Executive Summary
The 2007 top ten multinational pharmaceutical business events in China have been shortlisted as follows: 1) Eli Lilly & Co. put $100 million in Asian risk investment funds in China; 2) Roche established a drug R&D center in China; 3) Johnson & Johnson (China) mounted a buyback of Xian-Janssen shares; 4) Wyeth injected $58.5 million to expand its drug business; 5) Alliance BMP and Guangzhou Pharmaceutical Corp. established a joint venture; 6) GlaxoSmithKline's cervical cancer vaccine Cervarix launched in Macau; 7) Bayer acquired Topsun's OTC cough and cold medicine business; 8) Novartis boosted its OTC drug business; 9) Xian-Janssen broke ties with distributor Nanjing Pharmaceutical; 10) retail price dispute between TSKF and local drugstores. (Click here for more)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.